A method to screen a wide variety of drug candidates without laborious purification steps could advance the fight against drug-resistant bacteria.
ECOG-ACRIN launches new trial to evaluate nilotinib and paclitaxel for advanced cancers
The ECOG-ACRIN Cancer Research Group has enrolled the first patient in a new treatment trial to evaluate the effectiveness of adding nilotinib to standard paclitaxel